Parexel eyes a $150M share buyback

Parexel International ($PRXL) has approved a stock repurchase program of up to $150 million, and the company plans to use its existing cash and credit to buy up its own shares and boost investor value. The move comes after an up-and-down 12 months for Parexel, whose shares plummeted in the fall on concerns over net new business wins but have since climbed back to around $54, roughly gaining back all the value they lost. More

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.